ストックスクリーナーアプリを入手
5.21
9.22%
0.44
アフターアワーズ：
5.29
0.08
+1.54%
Arbutus Biopharma Corp (ABUS) 最新ニュース
Arbutus Biopharma (NASDAQ:ABUS) Capital Strategy Draws Attention - Kalkine Media
Why Is Arbutus Biopharma Stock Gaining Friday? - TradingView
ABUS Stock Pops As Moderna Settlement Transforms Balance Sheet - StocksToTrade
Why is Arbutus Biopharma stock surging today? - Investing.com
Why is Arbutus Biopharma stock surging today? By Investing.com - Investing.com UK
Arbutus Biopharma shares jump after unveiling $230 million share buyback plan - Yahoo Finance
ABUS Stock Surges 10% Today — What’s Driving This Super Rally? - Stocktwits
ABUS Looks 90.4% Undervalued on GF Value™ Despite Possible Value Trap - GuruFocus
Arbutus Biopharma stock surges on $230M buyback plan - Investing.com
Arbutus (NASDAQ: ABUS) plans Dutch auction share buyback - Stock Titan
ABUS Looks 90.4% Undervalued on GF Value™ - GuruFocus
Arbutus Biopharma Announces Plans for Up to $230 Million Modified Dutch Auction Tender Offer - Quiver Quantitative
Arbutus Announces Intent to Repurchase Up to US$230 Million - GlobeNewswire
Arbutus Plans $230 Million Share Buyback After Moderna Deal - MyChesCo
Moderna, Arbutus Clash On Gov't Venue For Vax IP Claims - Law360
Arbutus Biopharma (NASDAQ:ABUS) Cut to Hold at Wall Street Zen - MarketBeat
ABUS|Arbutus Biopharma Corp|Price:4.710|Chg%:+0.130 - TradingKey
Arbutus Biopharma (ABUS) Stock Profit Surge Leaves Durability Questions Open - simplywall.st
Morgan Stanley (ABUS) units report near-9% Arbutus Biopharma stake in 13G/A filing - Stock Titan
Arbutus Biopharma earnings matched, revenue topped estimates By Investing.com - Investing.com Nigeria
Arbutus Biopharma (NASDAQ:ABUS) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Arbutus Biopharma earnings matched, revenue topped estimates - Investing.com
Arbutus Biopharma Announces Q2 2026 Financial Results Highlighting Genevant License Revenue Impact - Kalkine Media
ABUS Looks 90.7% Undervalued on GF Value™ Despite Revenue Challe - GuruFocus
What's Next for Arbutus Biopharma Corp (ABUS) After Q2 Earnings - GuruFocus
Form 8K Arbutus Biopharma Corp For: 12 August By Investing.com - Investing.com Nigeria
Arbutus Biopharma Corp 2026: Revenue $1.01M, EPS ($0.03) — 10-Q Summary - TradingView
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Arbutus: Q2 Earnings Snapshot - KVUE
Arbutus Biopharma (ABUS) swings to $164.6M H1 profit on $178.4M Moderna payout - Stock Titan
American Public Education and Arbutus Biopharma Post Notable Stock Returns - MarketsMojo
Arbutus Biopharma (ABUS) Earnings Date and Reports 2026 - MarketBeat
Arbutus Biopharma (ABUS) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving AverageShould You Sell? - MarketBeat
Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage? - Yahoo Finance
Arbutus Biopharma Corp (I9DN.DU) stock price, news, quote and history - Yahoo Finance Australia
Arbutus Biopharma Corp (I9DN.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Arbutus Biopharma (ABUS) Institutional Ownership 2026 - MarketBeat
Arbutus Biopharma Corp (ABUS) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Arbutus Biopharma Corp expected to post a loss of 2 cents a shareEarnings Preview - TradingView
Arbutus Biopharma Corp (ABUS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ADAR1 Capital Management LLC Has $14.10 Million Position in Arbutus Biopharma Corporation $ABUS - MarketBeat
Arbutus Biopharma Corporation $ABUS Shares Acquired by Rubric Capital Management LP - MarketBeat
Arbutus Biopharma Corp (ABUS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Arbutus Biopharma Corp (ABUS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Arbutus Biopharma Corp (ABUS) Cash Flow - TradingKey
ABUS|Arbutus Biopharma Corp|Price:4.380|Chg%:-0.090 - TradingKey
Arbutus Biopharma Corp (ABUS) Balance Sheet - TradingKey
ABUS|Arbutus Biopharma Corp|Price:4.440|Chg%:+0.060 - TradingKey
TradingKey - TradingKey
Arbutus Biopharma Corp (ABUS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Arbutus Biopharma Corp (ABUS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arbutus Biopharma Corp (ABUS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arbutus Plans $230M Buyback as Patent Fight Expands - MyChesCo
US Seeks Toss Of Arbutus Patent Suit Over Moderna Vaccine - Law360
Arbutus (ABUS) Secures $178 Million Settlement with Moderna - GuruFocus
Arbutus Biopharma (ABUS) Files 8-K Announcing Agreement Termination and Key Company Details - Minichart
Arbutus Biopharma (ABUS) Files Lawsuits Against Pfizer and BioNT - GuruFocus
Arbutus (ABUS) Plans Share Buyback Program Starting Q3 - GuruFocus
Arbutus Biopharma Files International Patent Lawsuits Against Pfizer and BioNTech, Announces Moderna Settlement Payment and Plans for Capital Return - Quiver Quantitative
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders - The Manila Times
Arbutus awards litigation bonuses to CEO Lindsay Androski; CFO Tuan Nguyen to receive discretionary bonus - TradingView
1.21%
1.07%
大文字化:
|
ボリューム (24 時間):